ALZN · Alzamend Neuro, Inc.
$1.31
-0.04 (-2.96%)
At close · Jul 31
Going-concern doubt
— flagged Jul 22, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our audited financial statements are issued.”View the 10-K filed Jul 22, 2026
Market Cap
$6.28M
Shares
4.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.31
Open$1.36
Day$1.29–1.36
52W$0.84–2.68
Avg vol 30d236K
Short int328K · 6.9% float · 1.1d
Short vol33%
DataJun 2021–Jul 2026
Filing10-K · Jul 22
Up next
FQ2-27 quarter ends
~Oct 30, 2026
Est
filed Jul 22, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
+8%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
26%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
−34%
trailing
YTD return
−28%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
2 of 12 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.85% of float · ▲ +108.4% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 1-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+77%
Y/Y
Balance sheet
$710.7K
net cash
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
+8%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
26%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
2 of 12 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.85% of float · ▲ +108.4% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 26%
52-wk high $3
vs 200-day avg -23%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALZN
this stock
Alzamend Neuro, Inc.
|
$6.28M | -28.0% | — | — | 6.9% |
|
ONC
BeOne Medicines Ltd.
|
$456.72B | +4.0% | +22179.2% | 929.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$78.52B | -1.1% | +20.8% | 18.9 | 3.4% |
|
ARGX
Argenx SE
|
$53.42B | +1.5% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALZN | -1.5% | +12.9% | -33.8% | +9.2% | -28.0% |
| SPY | +1.1% | +0.3% | +8.2% | +0.0% | +9.6% |
| vs SPY | -2.6% | +12.6% | -42.0% | +9.1% | -37.6% |